Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC

NCT03884192 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT03884192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03884192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 3
Overall status
Unknown status
Start date
December 12, 2018
Completion date
December 30, 2021
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung